Tirzepatide Lilly - Search News

Lilly sues two medical spas over copycat weight-loss drugs

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

Hosted on MSN · 1d

Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Seeking Alpha · 5d

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Investor's Business Daily on MSN · 2d

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.

JD Supra1d

Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

FiercePharma13d

Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Hosted on MSN2d

Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...

BioSpace13d

Lilly Asks to Join GLP-1 Compounding Lawsuit

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Eli Lilly cuts FY24 revenue view to ~$45B from $45.4B-$46B, consensus $45.55B

While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...

BioSpace2d

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Yahoo Finance2d

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

pharmaphorum1d

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics